Immunic Inc
IMUX0.948USD
+0.016+1.75%
Market hours （ET）Quotes delayed by 15 min
85.44MMarket Cap
LossP/E TTM
More Details of Immunic Inc Company
Immunic, Inc. is a biotechnology company. The Company is focused on developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. The Company’s s lead development program, vidofludimus calcium (IMU-838), is in phase III and phase II clinical trials for the treatment of relapsing and progressive multiple sclerosis, respectively, and has shown therapeutic activity in phase II clinical trials in patients suffering from relapsing-remitting multiple sclerosis, progressive multiple sclerosis, and moderate-to-severe ulcerative colitis. IMU-856, which targets the protein Sirtuin 6 (SIRT6), is intended to restore intestinal barrier function and regenerate bowel epithelium, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease. IMU-381 is in preclinical testing, a next generation molecule being developed to specifically address the needs of gastrointestinal diseases.
Company Info
Ticker SymbolIMUX
Company nameImmunic Inc
IPO dateApr 17, 2014
CEODr. Daniel Vitt, Ph.D.
Number of employees91
Security typeOrdinary Share
Fiscal year-endApr 17
Address1200 Avenue Of The Americas
CityNEW YORK
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code10036
Phone13322559818
Websitehttps://imux.com/
Ticker SymbolIMUX
IPO dateApr 17, 2014
CEODr. Daniel Vitt, Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Daniel Vitt, Ph.D.
Dr. Daniel Vitt, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
391.88K
+3.98%
Dr. Joerg Neermann, Ph.D.
Dr. Joerg Neermann, Ph.D.
Independent Director
Independent Director
200.00K
+100.00%
Mr. Glenn Whaley, CPA
Mr. Glenn Whaley, CPA
Chief Financial Officer
Chief Financial Officer
95.51K
+89.09%
Dr. Duane D. Nash, M.D.
Dr. Duane D. Nash, M.D.
Executive Chairman of the Board
Executive Chairman of the Board
42.03K
+90.78%
Mr. Jason Tardio
Mr. Jason Tardio
President, Chief Operating Officer
President, Chief Operating Officer
12.51K
--
Ms. Simona Skerjanec, M.D.
Ms. Simona Skerjanec, M.D.
Independent Director
Independent Director
--
--
Dr. Andreas Muehler, M.D.
Dr. Andreas Muehler, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Inderpal Singh
Mr. Inderpal Singh
General Counsel
General Counsel
--
--
Ms. Maria Toernsen
Ms. Maria Toernsen
Independent Director
Independent Director
--
--
Dr. Hella Kohlhof, Ph.D.
Dr. Hella Kohlhof, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Daniel Vitt, Ph.D.
Dr. Daniel Vitt, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
391.88K
+3.98%
Dr. Joerg Neermann, Ph.D.
Dr. Joerg Neermann, Ph.D.
Independent Director
Independent Director
200.00K
+100.00%
Mr. Glenn Whaley, CPA
Mr. Glenn Whaley, CPA
Chief Financial Officer
Chief Financial Officer
95.51K
+89.09%
Dr. Duane D. Nash, M.D.
Dr. Duane D. Nash, M.D.
Executive Chairman of the Board
Executive Chairman of the Board
42.03K
+90.78%
Mr. Jason Tardio
Mr. Jason Tardio
President, Chief Operating Officer
President, Chief Operating Officer
12.51K
--
Ms. Simona Skerjanec, M.D.
Ms. Simona Skerjanec, M.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, May 17
Updated: Sat, May 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BVF Partners L.P.
9.29%
abrdn Inc.
8.60%
Soleus Capital Management, L.P.
7.61%
Avidity Partners Management LP
4.65%
The Vanguard Group, Inc.
4.10%
Other
65.74%
Shareholders
Shareholders
Proportion
BVF Partners L.P.
9.29%
abrdn Inc.
8.60%
Soleus Capital Management, L.P.
7.61%
Avidity Partners Management LP
4.65%
The Vanguard Group, Inc.
4.10%
Other
65.74%
Shareholder Types
Shareholders
Proportion
Hedge Fund
26.20%
Investment Advisor
13.30%
Investment Advisor/Hedge Fund
11.31%
Individual Investor
1.36%
Research Firm
1.05%
Pension Fund
0.06%
Other
46.74%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
135
51.29M
53.53%
-8.04M
2025Q1
143
43.91M
45.87%
-16.90M
2024Q4
141
54.47M
60.46%
-15.06M
2024Q3
152
61.42M
68.19%
-8.79M
2024Q2
169
63.34M
74.84%
-9.30M
2024Q1
202
64.86M
76.52%
-3.93M
2023Q4
199
22.30M
46.89%
-13.27M
2023Q3
205
25.26M
53.96%
-11.93M
2023Q2
209
27.09M
58.47%
-12.08M
2023Q1
208
31.66M
68.86%
-6.82M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BVF Partners L.P.
8.90M
9.29%
--
--
Mar 31, 2025
abrdn Inc.
1.06M
1.11%
+1.06M
--
Mar 31, 2025
Soleus Capital Management, L.P.
7.29M
7.61%
--
--
Mar 31, 2025
Avidity Partners Management LP
4.45M
4.65%
-3.51M
-44.09%
Mar 31, 2025
The Vanguard Group, Inc.
3.93M
4.1%
+7.79K
+0.20%
Mar 31, 2025
Focus Partners Wealth, LLC
2.58M
2.7%
+415.10K
+19.14%
Mar 31, 2025
Gratus Capital LLC
2.11M
2.2%
+56.86K
+2.77%
Jun 30, 2024
Omega Fund Management, LLC
1.79M
1.87%
--
--
Mar 31, 2025
Adage Capital Management, L.P.
1.40M
1.46%
--
--
Mar 31, 2025
Geode Capital Management, L.L.C.
976.15K
1.02%
+23.86K
+2.51%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
iShares Micro-Cap ETF
0.02%
Invesco NASDAQ Future Gen 200 ETF
0%
Avantis US Small Cap Equity ETF
0%
iShares Micro-Cap ETF
Proportion0.02%
Invesco NASDAQ Future Gen 200 ETF
Proportion0%
Avantis US Small Cap Equity ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
